NurExone Biologic Inc (TSXV: NRX) will seek shareholder approval on September 15, 2026, for a share consolidation of up to 30:1. The corporate action is intended to support the company’s strategy to list on a major US stock exchange.

The Toronto and Haifa-based biotech firm announced its annual general and special meeting of shareholders will take place at 2:00 pm Toronto time. The resolution requires an affirmative vote of not less than 66⅔% of votes cast by shareholders present.

Strategic Rationale

The Board of Directors believes the consolidation is a prudent enabling step in NurExone’s broader capital markets strategy. The company is evaluating potential US capital markets alternatives, including a possible future listing of shares on a major US stock exchange.

The proposed consolidation aims to help position the company to satisfy minimum bid price or similar listing requirements that may apply in connection with a potential future listing. The Board noted that the company’s current low nominal trading price may limit its ability to satisfy those requirements without implementing the consolidation.

Yoram Drucker, Chairman of the Board, stated that shareholder approval would provide additional flexibility as the company evaluates potential US capital markets alternatives and pursues the next phase of growth.

Implementation Details

If approved, the Board will be authorized to implement the consolidation within 36 months following shareholder approval. The exact timing and final ratio will be determined by the Board, which retains full discretion not to proceed if it determines it is no longer in the best interests of the company.

Implementation is subject to acceptance by the TSX Venture Exchange (TSXV) and receipt of all other required approvals. The Board believes providing flexibility on timing and ratio allows the company to account for market conditions and trading performance prior to implementation.

Eran Ovadya, Chief Financial Officer, noted that a higher anticipated post-consolidation trading price may improve marketability and allow engagement with additional institutional investors. However, he cautioned that there can be no assurance that the consolidation will improve liquidity, marketability, or trading price.

Other Agenda Items

At the meeting, shareholders will also be asked to elect directors and re-appoint the company’s auditor. Disinterested shareholders will consider the annual re-approval of the company’s amended and restated omnibus equity incentive plan.

Dr. Lior Shaltiel, Chief Executive Officer, said the proposed consolidation is intended to support the evolution of the company’s public market profile and share structure to align with US-listed biotechnology peers.

The company cautioned that no final decision has been made to pursue any US exchange listing, file a registration statement with the US Securities and Exchange Commission, or undertake a financing. Any potential US listing remains subject to numerous conditions, including final Board approval, TSXV acceptance, and satisfaction of all applicable listing standards.

NurExone Biologic Inc. (TSXV: NRX) has closed a non-brokered private placement raising aggregate gross proceeds of approximately C$1,066,078. The biopharmaceutical company issued 1,938,326 units at a price of C$0.55 per unit to fund general working capital purposes.

The closing is subject to final acceptance by the TSX Venture Exchange. No insiders participated in the offering, and the company did not pay any finder’s fees in connection with the transaction.

Offering Structure

Each unit consists of one common share and one common share purchase warrant. The warrants entitle holders to purchase one common share at an exercise price of C$0.69 per share for a period of 36 months from the closing date.

All securities issued under the offering are subject to a statutory hold period of four months and one day from the closing date, expiring on December 21, 2026.

Warrant Acceleration Clause

The warrants include an acceleration provision tied to trading performance. If the daily volume-weighted average trading price of the common shares on the TSX Venture Exchange equals or exceeds C$1.38 for any period of 20 consecutive trading days, the company may accelerate the expiry date of the warrants.

Upon providing written notice to warrant holders, the expiry date accelerates to 30 days following the date of the notice. If the warrants are not exercised by this accelerated expiry date, they will expire and be of no further force or effect.

What the Numbers Show

The warrant exercise price of C$0.69 represents a 25.5% premium over the unit subscription price of C$0.55. This structure provides immediate equity capital while creating upside potential for investors if the share price appreciates above the exercise threshold within the three-year window.

Company Background

NurExone is developing exosome-based regenerative therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. The company holds Orphan Drug Designation and aims to advance clinical trials in the U.S. and Europe through its U.S. subsidiary, Exo-Top Inc.